Portada›Viernes 21 de noviembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 21 de noviembre de 2025

Los 36 documentos que 26 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← jueves 20 de noviembre de 2025 · lunes 24 de noviembre de 2025 →

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

1. ASMBASSEMBLY BIOSCIENCES, INC.424B3Prospecto suplementario o de reventaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …Equity Agreements, Gilead made an upfront equity investment of $15 million by purchasing from us 13,073,668 shares at a purchase price of $1.16 per share (which was reduced to 1,089,472 shares when we effected a 1-for-12 reverse stock split in February 2024). As a part of the 2024 Financing 10 Table of Contents Transaction, we and Gilead entered into the 2024 Securities Purchase Agreement for the issuance and sale, in a private placement…
2. BCABBioAtla, Inc.424B5Nueva emisión de acciones con precioEDGAR
3. CLRBCellectar Biosciences, Inc.424B3Prospecto suplementario o de reventaEDGAR
   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …will send a deficiency notice to the company, advising that it has been afforded a “compliance period” of 180 calendar days to regain compliance with the applicable requirements. On January 30, 2025, we received a deficiency letter from Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00 per share required for continued listing on Nasdaq pursuant…

   En el documentoContrasplit de accionestexto original ▸

   …immediately following Bruton Tyrosine Kinase inhibitor (BTKi) treatment failures regardless of line of therapy. 4 Selected Financial Data Reverse Stock Split As previously disclosed, on June 24, 2025 we effected a reverse stock split of our outstanding shares of common stock at a ratio of one-for-thirty (the Reverse Stock Split). Our periodic and current reports that are incorporated by reference, and all other documents that were…
4. GNPXGenprex, Inc.424B5Nueva emisión de acciones con precioEDGAR
5. IKTInhibikase Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
6. OKUROnKure Therapeutics, Inc.424B3Prospecto suplementario o de reventaEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …liability company and a direct, wholly owned subsidiary of Reneo (“Merger Sub II”), and OnKure, Inc., a Delaware corporation (“Legacy OnKure”). Pursuant to the Merger Agreement, on the Closing Date, (i) Reneo effected a reverse stock split of Reneo’s issued common stock at a ratio of 1:10, (ii) Reneo changed its name to “OnKure Therapeutics, Inc.”, (iii) Reneo reclassified all of its common stock as “Class A common stock”, and (iv) Radiate…
7. PLYXPolaryx Therapeutics, Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …is substantial doubt about our ability to continue as a going concern. We have prepared cash flow forecasts which indicate that, based on our expected operating losses and negative cash flows, there is substantial doubt about our ability to continue as a going concern for the twelve months after the respective dates our financial statements for the year ended December 31, 2024 and the nine months ended September 30, 2025 were issued. As a result, management has included…

   En el documentoDebilidad material en el control internotexto original ▸

   …to decline. •Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval. •We previously identified a material weakness in our information technology general controls that has since been remediated. As a result of our remediation, we are currently evaluating if our internal controls are effective. If we experience additional…
8. TNXPTonix Pharmaceuticals Holding Corp.424B5Nueva emisión de acciones con precioEDGAR
9. CCCCC4 Therapeutics, Inc.S-3Capacidad de emisión registradaEDGAR
10. CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.S-3Capacidad de emisión registradaEDGAR
11. GNPXGenprex, Inc.S-1Capacidad de emisión registradaEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …Additionally, if the holders of Second Private Warrants exercise such warrants in full, we would receive additional net proceeds of approximately $6.1 million. At-The-Market Offering On December 13, 2023, we entered into an At The Market (“ATM”) Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program (the “2023 ATM Facility”) under which we may offer and…
12. TNGXTango Therapeutics, Inc.S-3Capacidad de emisión registradaEDGAR
13. TNGXTango Therapeutics, Inc.S-3ASRCapacidad de emisión registradaEDGAR

Participaciones y control

1. ANNXAnnexon, Inc.SC 13D/ACambio en participación significativaEDGAR
2. CYPHCYPHERPUNK TECHNOLOGIES INC.SC 13D/ACambio en participación significativaEDGAR
3. PGENPRECIGEN, INC.SC 13D/ACambio en participación significativaEDGAR
4. TNGXTango Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. CGEMCullinan Therapeutics, Inc.8-KFin de acuerdo materialEDGAR
2. ISPCiSpecimen Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
3. MBRXMoleculin Biotech, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
4. NMRANeumora Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
5. SHPHShuttle Pharmaceuticals Holdings, Inc.8-KFin de acuerdo materialEDGAR
6. TNGXTango Therapeutics, Inc.8-KFin de acuerdo materialEDGAR
7. ACTUACTUATE THERAPEUTICS, INC.8-KOtros hechos relevantesEDGAR
8. ANABANAPTYSBIO, INC8-KOtros hechos relevantesEDGAR
9. ANABANAPTYSBIO, INC8-KOtros hechos relevantesEDGAR
10. BCABBioAtla, Inc.8-KNuevo acuerdo materialEDGAR
11. BYSIBeyondSpring Inc.8-KNuevo acuerdo materialEDGAR
12. CNSPCNS Pharmaceuticals, Inc.8-KCambio en el consejo o la direcciónEDGAR
13. DWTXDogwood Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
14. GNPXGenprex, Inc.8-KOtros hechos relevantesEDGAR
15. IKTInhibikase Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
16. IMVTImmunovant, Inc.8-KCambio en el consejo o la direcciónEDGAR
17. NKTRNEKTAR THERAPEUTICS8-KCambio en el consejo o la direcciónEDGAR
18. TNXPTonix Pharmaceuticals Holding Corp.8-KNuevo acuerdo materialEDGAR

Juntas de accionistas

1. ISPCiSpecimen Inc.DEF 14AConvocatoria de junta de accionistasEDGAR

← jueves 20 de noviembre de 2025 · lunes 24 de noviembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.